TVM Capital is an institutional investor (Conventional VCs) founded in 1983 and headquartered in Munich, Germany. Venture capital investment firm. It provide capital and expertise to support breakthrough therapies and medical products. Its portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. It pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and company. It also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

Stage

early growth, expansion, growth capital, late-stage, commercialization stage, early growth, expansion, growth capital, late-stage, commercialization stage

Check size

$10M-$50M

HQ

Munich, Germany

Founded

1983

Website

https://tvm-capital.com

LinkedIn

https://linkedin.com/company/tvm-capital

Twitter

http://twitter.com/tvmcapital

What they look for

tech-enabled transformational healthcare companies; strong management teams; geography: MENA (Middle East/North Africa), Southeast Asia; post-seed/early VC with revenues and path to profitability; high growth/impact potential; good governance/ESG focus

Preparing to pitch TVM Capital?

CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.